Paper42434847
QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.
Montesinos P and 23 others. Future Oncol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia. Papers, record 42434847. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42434847
- Disease
- acute myeloid leukemia587 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| fms-Like Tyrosine Kinase 3 | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Phenylurea Compounds | Major topic |
| Benzothiazoles | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Humans | |
| Double-Blind Method | |
| Adult | |
| Female | |
| Male | |
| Treatment Outcome | |
| Middle Aged | |
| Aged | |
| Young Adult |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06578247 | Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Derived from the trial | Yes |
Source ClinicalTrials.gov
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35797463 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. | Blood | 2022 | https://conductscience.org/library/papers/35797463 | PubMed |
| 2 | 8182945 | Expression of the FLT3 gene in human leukemia-lymphoma cell lines. | Leukemia | 1994 | https://conductscience.org/library/papers/8182945 | PubMed |
| 3 | 37116523 | Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2023 | https://conductscience.org/library/papers/37116523 | PubMed |
| 4 | 18309032 | An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. | Blood | 2008 | https://conductscience.org/library/papers/18309032 | PubMed |
| 5 | 14673054 | Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/14673054 | PubMed |
| 6 | 41949390 | Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First. | Blood Adv | 2026 | https://conductscience.org/library/papers/41949390 | PubMed |
| 7 | 26376137 | Acute Myeloid Leukemia. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26376137 | PubMed |
| 8 | 39392050 | In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia. | Mol Med Rep | 2024 | https://conductscience.org/library/papers/39392050 | PubMed |
| 9 | 29257272 | High expression of FLT3 is a risk factor in leukemia. | Mol Med Rep | 2018 | https://conductscience.org/library/papers/29257272 | PubMed |
| 10 | 30651634 | Targeting FLT3 mutations in AML: review of current knowledge and evidence. | Leukemia | 2019 | https://conductscience.org/library/papers/30651634 | PubMed |
| 11 | 31821677 | FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. | Cancer Sci | 2020 | https://conductscience.org/library/papers/31821677 | PubMed |
| 12 | 27367478 | 'Acute myeloid leukemia: a comprehensive review and 2016 update'. | Blood Cancer J | 2016 | https://conductscience.org/library/papers/27367478 | PubMed |
| 13 | 33603142 | Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. | Leukemia | 2021 | https://conductscience.org/library/papers/33603142 | PubMed |
| 14 | 40008144 | Bone marrow immune cells and drug resistance in acute myeloid leukemia. | Exp Biol Med (Maywood) | 2025 | https://conductscience.org/library/papers/40008144 | PubMed |
| 15 | 8637232 | Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. | Leukemia | 1996 | https://conductscience.org/library/papers/8637232 | PubMed |
| 16 | 12200684 | Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. | Leukemia | 2002 | https://conductscience.org/library/papers/12200684 | PubMed |
| 17 | 32215183 | Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells. | Oncotarget | 2020 | https://conductscience.org/library/papers/32215183 | PubMed |
| 18 | 9737679 | Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. | Leukemia | 1998 | https://conductscience.org/library/papers/9737679 | PubMed |
| 19 | 24002496 | Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/24002496 | PubMed |
| 20 | 33425766 | FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. | Front Oncol | 2020 | https://conductscience.org/library/papers/33425766 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| FLT3 | 2322 | PubTator's text mining | https://conductscience.org/library/genes/2322 |
Source NCBI Gene
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| QUIZARTINIB | CHEMBL576982 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL576982 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Cited by
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42434847
GET https://conductscience.org/api/papers/v1/42434847/authors?page=2